Pharmacological interventions for spasticity following spinal cord injury: Results of a Cochrane systematic review

Europa Medicophysica

Volumn 42, Issue 1, 2006, Pages 5-15

  Taricco, M ^a   Pagliacci, M C ^b   Telaro, E ^c   Adone, R ^d  

^a RHO HOSPITAL   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Rehabilitation Unit   (Italy)

Author keywords

Review; Spasticity; Spinal cord injury, Randomized controlled trials

Indexed keywords

AMOBARBITAL; BACLOFEN; CLONIDINE; DANTROLENE; DIAZEPAM; GABAPENTIN; PLACEBO; TIZANIDINE;

CLINICAL TRIAL; DAILY LIFE ACTIVITY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; REVIEW; SPASTICITY; SPINAL CORD INJURY; SYSTEMATIC REVIEW; XEROSTOMIA;

BACLOFEN; CLONIDINE; DANTROLENE; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; RANDOMIZED CONTROLLED TRIALS; SPINAL CORD INJURIES;

EID: 33646489781     PISSN: 00142573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Maynard FM, Karunas RS, Waring WP. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil 1990;71:566-9.
2. Walter JS, Sacks J, Othman R, Rankin AZ, Nemchausky B, Chintam R et al. A database of self-reported secondary medical problems among VA SCI patients: its role in clinical care and management. J Rehabil Res Dev 2002;39:53-61.
3. Noreau L, Proulx P, Gagnon L, Drolet M, Laramee MT. Secondary impairments after spinal cord injury. A population-based study. Am J Phys Med Rehabil 2000;79:526-41.
4. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13-6.
5. Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo MT, McCann MT et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000;38:7-15.
6. Richardson D, Sheen G, Werring D, Desai M, Edwards S, Greenwood R et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
7. Creedon SD, Dijkers MP, Hinderer SR. Intrathecal baclofen for severe spasticity: a metanalysis. Int J Rehabil Health 1997;3:171-85.
8. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 1996;77:713-6.
9. Katz RT, Rymer WZ. Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil 1989;70:144-55.
10. Bohannon RW, Smith MNB. Interrater reliability of modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
11. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
12. Ashby P, Burke D, Rao S, Jones RF. Assessment of cyclobenzaprine in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1972;35:599-605.
13. Basmajian JV, Super GA. Dantrolene sodium in the treatment of spasticity. Arch Phys Med Rehabil 1973;54:61-4.
14. Basmajian JV, Yucel V. Effects of a GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study. Am J Phys Med 1974;53:223-8.
15. Bokonjic R, Dimitrijevic J. Medication of spasticity with a combination of glycine and folic acid - double blind study] Med Arh 1979;33:403-6. Croatian.
16. Bovier P, Cambier J, Morselli PL. [Double blind study of progabide in spasticity] Therapie 1985;40:181-5. French.
17. Cocchiarella A, Downey JA, Darling RC. Evaluation of the effect of diazepam on spasticity. Arch Phys Med Rehabil 1967;48:393-6.
18. Cohan SL, Raines A, Panagakos J, Armitage P. Phenytoin and Chlorpromazine in the treatment of spasticity. Arch Neurol 1980;37:360-4.
19. Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 1974;12:170-4.
20. Growdon JH, Nader TM, Schoenfeld J, Wurtman RJ. L-threonine in the treatment of spasticity. Clin Neuropharmacol 1991;14:403-12.
21. Harvey MS. A comparative trial of dimethothiazine in spastic conditions. Practitioner 1974;213:101-5.
22. Haslam RH, Walcher JR, Lietman PS, Kallman CH, Mellitis ED. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55:384-8.
23. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. BMJ 1971;4:131-4.
24. Hudgson P, Weightman D, Cartlidge NE. Clinical trial of baclofen against placebo. Postgrad Med J 1972;Suppl 5:37-40.
25. Lee A, Patterson V. A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88:334-8.
26. Levine IM, Jossmann PB, Rudd J, De Angelis V. The quantitative evaluation of intravenous methocarbamol in the relief of spasticity. Neurology 1968;18:69-74.
27. Levine IM, Jossmann PB, Friend DG, De Angelis V. Prazepam in the treatment of spasticity. A quantitative double-blind evaluation. Neurology 1969;19:510-6.
28. Levine IM, Jossmann PB, DeAngelis V. Lioresal, a new muscle relaxant in the treatment of spasticity-a double-blind quantitative evaluation. Dis Nerv Syst 1977;38:1011-5.
29. Losin S, McKean CM. Chlorzoxazone (paraflex) in the treatment of severe spasticity. Dev Med Child Neurol 1966;8:768-9.
30. Lossius R, Dietrichson P, Lunde PK. Effect of clorazeprate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations. Acta Neurol Scand 1985;71:190-4.
31. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T et al. Effect of intrathecal baclofen delivered by an implanted pragrammable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-9.
32. Monstor AW, Herman R, Meeks S, McHenry J. Cooperative study for assessing the effects of a pharmacological agent on spasticity. Am J Phys Med 1973;52:163-88.
33. O'Brien CF, Simpson DM, Alexander D, Tagliati M, Aswad AS, Gibson J et al. A randomised double blind placebo controlled study to evaluate the use of botulinum toxin type A in the treatment of spasticity. Neurology 1995;45 Suppl 4:A329.
34. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996;85:452-7.
35. Pagano MA, Ferreiro ME, Herskovits E. [Comparative study of tizanidine and baclofen in patients with chronic spasticity] Rev Neurol Arg 1990;15:27-33. Spanish.
36. Pedersen E, Arlien Soborg P, Grynderup V, Henriksen O. Gaba derivative in spasticity (Beta -(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba). Acta Neurol Scand 1970;46:257-66.
37. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1985;4:278-84.
38. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976;33:403-6.
39. Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978;221:123-7.
40. Wilson LA, McKechnie AA. Oral diazepam in the treatment of spasticity in paraplegia a double-blind trial and subsequent impressions. Scott Med J 1966;11:46-51.
41. Hinderer SR, Lehmann JF, Price R, White O, deLateur BJ, Deitz J. Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 1990;69:311-7.
42. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;27:296-301.
43. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997;35:171-5.
44. Segal JL, Pathak MS, Hernandez JP, Himber PL, Brunnemann SR, Charter RS. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19:713-23.
45. Wainberg M, Barbeau H, Gauthier S. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries. J Neurol Neurosurg Psychiatry 1990;53:754-63.
46. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow up. Arch Phys Med Rehabil 1996;77:35-9.
47. Broseta J, Morales F, Garcia March G, Sanchez Ledesma MJ, Anaya J, Gonzalez Darder J et al. Use of intrathecal baclofen administered by programmable infusion pumps in resistent spasticity. Acta Neurochir Suppl (Wien) 1989;46:39-45.
48. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
49. Fung J, Stewart JE, Barbeau H. The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects. J Neurol Sci 1990;100:85-93.
50. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Neurol Sci 1990;240:1-4.
51. Parke B, Penn RD, Savoy SM, Corcos D. Functional outcomes after delivery of intrathecal baclofen. Arch Phys Med Rehabil 1989;70:30-2.
52. Pirotte B, Heilporn A, Joffroy A, Zegers de Beyl D, Wesel P, Brotchi J et al. Chronic intrathecal baclofen in severely disabling spasticity: selection, clinical assessment and long-term benefit. Acta Neurol Belg 1995;95:216-25.
53. Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo MT, McCann MT et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000;38:7-15.
54. Chan A, Hugos C, Morrison S, Theriot K. Balance and spasticity: what we know and what we believe. J Neurol Rehabil 1994;8:119-30.
55. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994;17:150-6.
56. Postma TJ, Oenema D, Terpstra S, Bouma J, Kuipers, Upmeijer et al. Cost analysis of the treatment of severe spinal spasticity with a continuos intrathecal baclofen infusion system. Pharmacoeconomics 1999;15:395-404.
57. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21.
58. Hugenholts H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity-a double blind crossover study in eight patients. Can J Neurol Sci 1992;19:188-95.
59. Kravitz HM, Corcos DM, Hansen G, Penn RD, Cartwright RD, Gianino J. Intrathecal baclofen. Effects on nocturnal leg muscle spasticity. Am J Phys Med Rehabil 1992;71:48-52.
60. Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci 1991;18:321-32.
61. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35:686-9.
62. Corbett M, Frankel HL, Michaelis L. A double blind, cross-over trial of valium in the treatment of spasticity. Paraplegia 1972;10:19-22.
63. Jones RF, Burke D, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry 1970;33:464-8.
64. Burke D, Gillies JD, Lance JW. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proc Aust Assoc Neurol 1971;8:131-4.
65. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994;17:150-6.
66. Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 2005;86:2165-71.